 Intranasal administration neostigmine potentiates intravenous intranasal growth hormone GH hormone-induced GH release short children Administration cholinergic agonists basal GH-releasing hormone GHRH GH secretion inhibition endogenous somatostatin release aim study groups children idiopathic short stature effect intranasal administration neostigmine inNS mg cholinesterase inhibitor basal GH levels somatotroph response GHRH peptide iv ivGHRH microgram/kg inGHRH micrograms/kg group age yr inNS significant GH increase saline area curve AUC mean SEM micrograms/L.h somatotroph response inNS ivGHRH ivGHRH micrograms/L.h group age yr ivGHRH GH rise inGHRH micrograms/L.h Administration inNS GH rise similar inGHRH AUC micrograms/L.h inGHRH-induced GH response micrograms/L.h inNS inGHRH ivGHRH conclusion cholinergic agonists neostigmine able basal GHRH-induced GH secretion short children intranasal administration neostigmine GHRH micrograms/kg able GH rise similar ivGHRH microgram/kg potential usefulness combination cocktail route administration treatment short stature